Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Biological Chemistry

Greater Selectivity Refines Treatment Of Cognitive Disorders

Experimental compound targets specific receptor class involved in Alzheimer's disease

by Sophie L. Rovner
August 31, 2009 | A version of this story appeared in Volume 87, Issue 35

Alzheimer’s disease destroys memory by degrading neurons that pass signals with the help of the neurotransmitter acetylcholine. Current treatments compensate by increasing acetylcholine levels in the brain, but these drugs offer only modest benefits. They also cause side effects because the extra neurotransmitter activates some classes of acetylcholine receptors that aren’t involved in cognition. Now, researchers at Merck Research Laboratories in West Point, Pa., have identified a compound that selectively boosts the activity of the specific acetylcholine receptor—known as M1—that’s associated with cognition. William J. Ray and colleagues zeroed in on the compound, benzyl quinolone carboxylic acid (BQCA), by screening more than 1 million substances (Proc. Natl. Acad. Sci. USA, DOI: 10.1073/pnas.0900903106). The researchers showed that this orally active compound improves memory in mice. They also found that BQCA is an allosteric modulator that alters the M1 receptor’s conformation, thereby reducing the amount of acetylcholine necessary to activate it. Allosteric modulation represents a promising therapeutic strategy for Alzheimer’s and other cognitive disorders, Ray notes.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.